Ulcerative Colitis
- Infliximab vs Tofacitinib Linked to Better Clinical Response in Biologic-Naive Patients With UC
- Generic Version Uceris Rectal Foam Now Available
- Which Patients With Ulcerative Colitis Are at Increased Risk for Multiple Myeloma?
- Etrasimod Shows Favorable Results for Treating Ulcerative Colitis
- FDA to Review SC Formulation of Vedolizumab for Ulcerative Colitis
- Filgotinib Effective as Both First- and Second-Line Treatment in Ulcerative Colitis
- Vedolizumab a Viable Treatment Option for Chronic Pouchitis in Ulcerative Colitis
- Upadacitinib Linked to Greatest Likelihood of Early Remission in Active UC
- Mirikizumab Approval Denied Over Issues Related to Proposed Manufacturing
- Filgotinib May Have Superior Efficacy to Vedolizumab in Severely Active Ulcerative Colitis
- Higher Olamkicept Dose Achieves Greater Ulcerative Colitis Clinical Response
- Tofacitinib May Effectively Treat Refractory Acute, Severe Ulcerative Colitis
Clinical Tools
Powered by
Powered by 
